RAS oncogenic signal upregulates EZH2 in pancreatic cancer

Biochemical and Biophysical Research Communications

Volumn 417, Issue 3, 2012, Pages 1074-1079

  Fujii, Satoshi ^a   Fukamachi, Katsumi ^b   Tsuda, Hiroyuki ^b   Ito, Kosei ^c   Ito, Yoshiaki ^d   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

EZH2; Pancreatic cancer; RAS; RUNX3

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MUTANT PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSGENIC RAT; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RATS; RATS, TRANSGENIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UP-REGULATION;

ANIMALIA; RATTUS;

EID: 84855989975     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.099     Document Type: Article

References (20)

1. Shih T.Y., Papageorge A.G., Stokes P.E., Weeks M.O. Scolnick EM: Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus. Nature 1980, 287:686-691.
2. Schuettengruber B., Chourrout D., Vervoort M., Leblanc B. Cavalli G: Genome regulation by polycomb and trithorax proteins. Cell 2007, 128:735-745.
3. Plath K., Fang J., Mlynarczyk-Evans S.K., Cao R., Worringer K.A., Wang H., de la Cruz C.C., Otte A.P., Panning B., Zhang Y. Role of histone H3 lysine 27 methylation in X inactivation. Science 2003, 300:131-135.
4. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
5. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100:11606-11611.
6. Fujii S., Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci. 2008, 99:738-746.
7. Fujii S., Ito K., Ito Y., Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 2008, 283:17324-17332.
8. Li X., Gonzalez M.E., Toy K., Filzen T., Merajver S.D., Kleer C.G. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am. J. Pathol. 2009, 175:1246-1254.
9. Ding L., Erdmann C., Chinnaiyan A.M., Merajver S.D., Kleer C.G. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 2006, 66:4095-4099.
10. Fujii S., Tokita K., Wada N., Ito K., Yamauchi C., Ito Y., Ochiai A. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 2011, 30:4118-4128.
11. Ueda S., Fukamachi K., Matsuoka Y., Takasuka N., Takeshita F., Naito A., Iigo M., Alexander D.B., Moore M.A., Saito I., Ochiya T., Tsuda H. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human HRAS oncogene in rat pancreas. Carcinogenesis 2006, 27:2497-2510.
12. Tsuda H., Fukamachi K., Ohshima Y., Ueda S., Matsuoka Y., Hamaguchi T., Ohnishi T., Takasuka N., Naito A. High susceptibility of human c-HRAS proto-oncogene transgenic rats to carcinogenesis: a cancer-prone animal model. Cancer Sci. 2005, 96:309-316.
13. Tanaka H., Fukamachi K., Futakuchi M., Alexander D.B., Long N., Tamamushi S., Minami K., Seino S., Ohara H., Joh T., Tsuda H. Mature acinar cells are refractory to carcinoma development by targeted activation of RAS oncogene in adult rats. Cancer Sci. 2010, 101:341-346.
14. Fukamachi K., Tanaka H., Hagiwara Y., Ohara H., Joh T., Iigo M., Alexander D.B., Xu J., Long N., Takigahira M., Yanagihara K., Hino O., Saito I., Tsuda H. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. Biochem. Biophys. Res. Commun. 2009, 390:636-641.
15. Fujii S., Luo R.Z., Yuan J., Kadota M., Oshimura M., Dent S.R., Kondo Y., Issa J.P., Bast R.C., Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum. Mol. Genet. 2003, 12:1791-1800.
16. Ito K., Inoue K.I., Bae S.C., Ito Y. Runx3 expression in gastrointestinal tract epithelium: resolving the controversy. Oncogene 2009, 28:1379-1384.
17. Watanabe M., Nobuta A., Tanaka J., Asaka M. An effect of KRAS gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int. J. Cancer 1996, 67:264-268.
18. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
19. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-I S., Wada H., Fujimoto J., Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
20. Saxena N., Lahiri S.S., Hambarde S., Tripathi R.P. RAS: target for cancer therapy. Cancer Invest. 2008, 26:948-955.